<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144746">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02076685</url>
  </required_header>
  <id_info>
    <org_study_id>200805015M</org_study_id>
    <nct_id>NCT02076685</nct_id>
  </id_info>
  <brief_title>NAT2 Genotyping in Re-challenge Protocol of INH Titration in Patients With Anti-TB Medications-induced Hepatitis</brief_title>
  <official_title>The Application of the N-acetyltransferase 2 (NAT2) Genotyping in Re-challenge Protocol of Isoniazid (INH) Titration in Patients With Anti-TB Medications-induced Hepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <authority>Taiwan: Department of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To improve the treatment outcome in patients with tuberculosis and integrate the
      pharmacogenetics into clinical practice, the information of NAT2 genotyping was used in
      re-challenge protocol for isoniazid (INH) titration in patients with anti-tuberculosis
      medication-induced hepatitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>successful re-use of isoniazid for TB treatment</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>In this study, we would like to test the hypothesis of NAT2 genotyping helping in isoniazid rechallenge after patients experienced adverse effects of anti-TB treatment. Therefore, to observe the patients can re-use isoniazid successfully is an important outcome measure in this study.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatotoxicity</condition>
  <arm_group>
    <arm_group_label>isoniazid rechalleng</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>When patients encountered hepatotoxicity during the anti-TB treatment, genotyping and pk study of INH would be performed and dose adjustment accordingly.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isoniazid</intervention_name>
    <description>dose adjustment according to the pharmacogenomic results</description>
    <arm_group_label>isoniazid rechalleng</arm_group_label>
    <other_name>Duracin, Rifina</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. &gt;= 18 years.

          2. Take INH for at least a week.

          3. abnormal liver function (ALT (alanine, transaminase) increased by more than three
             times the upper limit of normal, or ALT higher than twice the upper limit of normal
             and total bilirubin higher than 2.0 mg / dL

        Exclusion Criteria:

        1.Taking INH before liver function abnormalities. 2.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shen Li Jiuan, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nationa Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li-Jiuan Shen, Ph.D.</last_name>
    <email>ljshen@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li-Jiuan Shen, Ph.D.</last_name>
      <email>ljshen@ntu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Li-Jiuan Shen, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 13, 2014</lastchanged_date>
  <firstreceived_date>November 16, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacogenetics</keyword>
  <keyword>anti-tuberculosis drug</keyword>
  <keyword>genetic polymorphism</keyword>
  <keyword>isoniazid</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Isoniazid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
